$SNSS Sunesis: Despite Primary Endpoint Miss Vosaroxin Still Holds Value, Says Cowen http://www.smarteranalyst.com/2014/10/06/sunesis-despite-primary-endpoint-miss-vosaroxin-still-holds-value-says-cowen/